Key facts
- On August 21, 2026, the FDA issued marketing granted orders for 11 ZYN ULTRA pouches from Swedish Match USA (Philip Morris International’s US affiliate): ten at 9mg and one, Smooth, at 11mg
- This is a standard marketing authorization (permission to sell), not the “lower risk than cigarettes” advertising claim ZYN’s 3mg/6mg lineup won on July 2. The FDA found these pouches carry lower levels of most harmful and potentially harmful constituents (HPHCs) than other oral and smokeless tobacco, many too low to quantify, but no reduced-risk claim attaches to the ULTRA line
- 9mg and 11mg is roughly double to triple standard ZYN’s usual range, and it brings the FDA’s total authorized nicotine pouch count to 43.
The FDA has cleared Philip Morris to sell its strongest ZYN pouches yet. On August 21 the agency granted marketing orders to Swedish Match USA for 11 products under the new ZYN ULTRA name: Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Spearmint, Wintergreen and Wintergreen Chill at 9mg, plus Smooth in both 9mg and 11mg.
Here’s the distinction worth getting right. This is not the “lower risk than cigarettes” claim ZYN won for its standard 3mg/6mg lineup on July 2. That was a rarer modified-risk order letting the company advertise a specific health claim. The ULTRA authorization is the ordinary kind: permission to sell, grounded in the FDA’s finding that the products carry lower levels of most HPHCs than other smokeless tobacco, and that company data showed they appeal mainly to adults who already smoke or use smokeless tobacco. Nothing here lets Swedish Match put a reduced-risk claim on the ULTRA can.
What it means for you. If you already use ZYN and you’re not struggling with cravings, there’s no reason to size up: 9mg and 11mg pouches deliver meaningfully more nicotine per pouch than the standard 3mg/6mg strengths (our nicotine strengths guide breaks down what those numbers actually mean, and here’s how a pouch compares to a cigarette as an honest baseline). ULTRA is aimed at smokers who need a bigger nicotine hit to fully switch off cigarettes, not at people already managing on lower strengths. Going up a tier just to go up a tier tends to raise your baseline need rather than lower it. If your goal is stepping down or off nicotine entirely, nicotine-free options exist too.
The pushback is about dependence, not just flavors this time. Public health researchers have flagged that higher-nicotine formulations carry a real risk: more nicotine exposure trains the brain to produce more nicotine receptors, which raises how much a person needs just to feel normal. The FDA’s own framing cuts both ways: it says the higher strength can help smokers with heavier habits switch completely, while critics counter that a stronger pouch is also a stronger addiction risk for anyone who starts on it nicotine-naive.
More ULTRA strengths reportedly remain under FDA review, so this isn’t the last word on how high the pouch market goes. The one to watch is whether ULTRA’s user base turns out to be smokers trading up from cigarettes, or existing ZYN users trading up from 6mg: that’s what will decide if this reads as harm reduction or dose creep.
